Related Experiment Video
Updated: Jan 4, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Evaluation of PAP in EGFR Mutational Testing in Advanced NSCLC: a Comparative Study
Background:
EGFR mutational testing is crucial for advanced non-squamous NSCLC. PAP is a sensitive and selective method to detect rare mutations.
Methods:
Eighty-five patients with non-squamous NSCLC were enrolled in this study. A set of paired plasma samples from each patient were collected and detected by PAP and ARMS.
Results:
Of 85 paired samples, 78.8% (67/85) presented the same mutational status by the two methods. There was no statistically significant difference between the mutation frequencies in plasma samples detected with PAP and ARMS (p = 0.096).
Conclusions:
PAP technology appears to be an alternative choice with relatively high sensitivity for the detection of plasma EGFR mutations.
